hr17031
Peptideexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Sep 2, 2021 (NCT05031871)
Timeline
Indications
Studied for
Mechanism of action
GLP1R agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06871761 | Phase 3 | May 8, 2024 | Hengrui Therapeutics, Inc. |
| NCT06881264 | Phase 3 | Apr 30, 2024 | Hengrui Therapeutics, Inc. |
| NCT06086912 | Phase 1 | Nov 7, 2023 | Hengrui Therapeutics, Inc. |
| NCT05333835 | Phase 2 | Jul 8, 2022 | Hengrui Therapeutics, Inc. |
| NCT05292495 | Phase 1 | Mar 31, 2022 | Hengrui Therapeutics, Inc. |
| NCT05151705 | Phase 1 | Dec 20, 2021 | Hengrui Therapeutics, Inc. |
| NCT05031871 | Phase 1 | Sep 2, 2021 | Hengrui Therapeutics, Inc. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hengrui Therapeutics, Inc. | For profit | 7 | 7 | 3 | 2021 |
1 organizations
Page 1 / 1